← Back to Search

CAR T-cell Therapy

Armed Activated T-Cells for Pancreatic Cancer

Phase 1
Waitlist Available
Led By Kenneth Yu, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Must have metastatic pancreatic cancer and have received at least first-line chemotherapy
Histological or cytological proof of pancreatic adenocarcinoma
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial is testing a new cancer treatment to see if it is safe and effective for people with advanced pancreatic cancer.

Who is the study for?
This trial is for adults with advanced pancreatic cancer who've had first-line chemo. They should have stable or progressing disease after treatment, good performance status (able to carry out daily activities), and adequate organ function. Pregnant women can't join, nor those breastfeeding or with certain medical conditions that could affect compliance.Check my eligibility
What is being tested?
The study tests EGFR-BATs (anti-EGFR-bispecific antibody armed activated T-cells) in patients to determine the safest dose and side effects. Participants must have previously received standard chemotherapy for their condition.See study design
What are the potential side effects?
Potential side effects may include reactions related to immune system activation, such as inflammation in various organs, infusion-related reactions, fatigue, increased risk of infection due to immune response alteration, and possible allergic reactions if sensitive to components like cetuximab.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I have pancreatic cancer that has spread and received first-line chemotherapy.
My diagnosis is pancreatic cancer, confirmed by lab tests.
I am of childbearing age and have a recent negative pregnancy test.
I am mostly able to care for myself and perform daily activities.
My kidney function is within the required range.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Evaluate toxicity

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pancreatic AdenocarcinomaExperimental Treatment1 Intervention
Participants have metastatic pancreatic cancer who have received at least first line chemotherapy and have disease progression during or within 6 months of treatment.

Find a Location

Who is running the clinical trial?

University of VirginiaOTHER
757 Previous Clinical Trials
1,245,241 Total Patients Enrolled
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,938 Previous Clinical Trials
588,368 Total Patients Enrolled
Kenneth Yu, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Media Library

anti-EGFR-bispecific antibody armed activated T-cells (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04137536 — Phase 1
Pancreatic Cancer Research Study Groups: Pancreatic Adenocarcinoma
Pancreatic Cancer Clinical Trial 2023: anti-EGFR-bispecific antibody armed activated T-cells Highlights & Side Effects. Trial Name: NCT04137536 — Phase 1
anti-EGFR-bispecific antibody armed activated T-cells (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04137536 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent does utilization of an anti-EGFR-bispecific antibody armed activated T-cells pose a risk to subjects?

"The anti-EGFR bispecific antibody armed activated T cells have been assigned a score of 1, as this is an early Phase 1 trial which has only limited evidence to support its safety and efficacy."

Answered by AI

Is there an ongoing search for volunteers to participate in this research study?

"According to the material on clinicaltrials.gov, this trial is not actively seeking participants at present. Initially posted on October 17th 2019 and modified most recently on October 7th 2022, it does not have any available openings for enrolment; however there are still 757 other trials recruiting potential candidates right now."

Answered by AI

Who else is applying?

What state do they live in?
How old are they?
18 - 65
What site did they apply to?
University of Virginia (Specimen Analysis)
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
~1 spots leftby Apr 2025